Pharminox is engaged in the discovery, research and development of novel small molecule drugs to treat common forms of cancer, with a specific research focus on molecularly targeted DNA damage and inhibition of DNA damage repair mechanisms.
The company has world-class expertise in medicinal chemistry and exceptional experience in the discovery, research and development of cancer therapeutics.
The management team is led by CEO Peter Worrall (ex Vernalis, British Biotech) and Research Director Marc Hummersone (ex KuDOS Pharmaceuticals), and supported by an extensive network of consultants and advisers.Between them the Pharminox team have proven track records in the discovery and development of several leading marketed anti-cancer agents, including the blockbuster drugs temozolomide (Temodar, Schering Plough) for the treatment of glioblastoma mutliforme (brain cancer), which was discovered by the Company's CSO Emeritus, Professor Malcolm Stevens OBE, FRS, and erlotinib (Tarceva, Genentech and OSI Pharmaceuticals) for the treatment of lung cancer.
Through internal drug discovery combined with selective acquisition of appropriate external research and development opportunities, Pharminox is building a focused pipeline of proprietary programmes that include completely new classes of anti-cancer agent with novel mechanisms of action, offering the prospect of first-in-class compounds with multiple applicability across a range of different cancers. Our portfolio includes:
Pharminox was formed in 2002 as a spin-out from Oxford University. Our operations are now based at the BioCity facility in Nottingham, UK. The Company's investors include IP Group plc, IP Venture Fund, Oxford University and a number of private investors, management and employees.
The company's strategy is to progress its discovery programmes into the early stages of development, typically late preclinical or early clinical development, and then to outlicense to a large partner for onward development and commercialisation